Silver Oak Securities Incorporated acquired a new position in shares of STERIS plc (NYSE:STE – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 3,412 shares of the medical equipment provider’s stock, valued at approximately $717,000.
Several other large investors have also modified their holdings of STE. Wellington Management Group LLP grew its holdings in shares of STERIS by 21.9% in the 2nd quarter. Wellington Management Group LLP now owns 3,502,897 shares of the medical equipment provider’s stock worth $737,605,000 after acquiring an additional 629,532 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of STERIS by 25.7% during the first quarter. Janus Henderson Group PLC now owns 1,863,139 shares of the medical equipment provider’s stock worth $411,995,000 after purchasing an additional 380,504 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of STERIS by 4.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,113,845 shares of the medical equipment provider’s stock valued at $246,295,000 after purchasing an additional 46,391 shares during the last quarter. Amundi lifted its holdings in shares of STERIS by 43.2% during the first quarter. Amundi now owns 771,092 shares of the medical equipment provider’s stock valued at $170,512,000 after purchasing an additional 232,520 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of STERIS by 20.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 519,511 shares of the medical equipment provider’s stock valued at $114,879,000 after purchasing an additional 88,872 shares during the last quarter. 94.69% of the stock is owned by institutional investors.
STERIS Trading Down 1.7%
NYSE STE opened at $257.42 on Wednesday. STERIS plc has a twelve month low of $195.14 and a twelve month high of $269.44. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.44 and a current ratio of 2.05. The stock has a market cap of $25.00 billion, a price-to-earnings ratio of 24.05 and a beta of 0.86. The firm’s 50 day moving average price is $224.80 and its two-hundred day moving average price is $224.59.
STERIS (NYSE:STE – Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical equipment provider reported $2.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.26. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.56 billion. STERIS had a net margin of 13.41% and a return on equity of 14.80%. The company’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.47 EPS. Equities analysts anticipate that STERIS plc will post 11.46 EPS for the current year.
STERIS Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Tuesday, November 17th will be issued a dividend of $0.69 per share. The ex-dividend date is Tuesday, November 17th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 1.1%. STERIS’s payout ratio is currently 32.74%.
Insider Activity
In related news, Director Mohsen Sohi sold 4,893 shares of the stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $253.22, for a total value of $1,239,005.46. Following the completion of the sale, the director directly owned 24,305 shares of the company’s stock, valued at approximately $6,154,512.10. This represents a 16.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Karen L. Burton sold 5,880 shares of the stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $255.62, for a total value of $1,503,045.60. Following the completion of the sale, the chief financial officer directly owned 12,956 shares of the company’s stock, valued at approximately $3,311,812.72. This represents a 31.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 12,819 shares of company stock worth $3,274,011. 1.12% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on STE shares. UBS Group decreased their price target on STERIS from $275.00 to $270.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Morgan Stanley upgraded STERIS from an “overweight” rating to a “buy” rating in a report on Friday. KeyCorp boosted their price objective on STERIS from $269.00 to $284.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. Jefferies Financial Group raised shares of STERIS from a “hold” rating to a “buy” rating and upped their price objective for the company from $232.00 to $305.00 in a research note on Friday. Finally, Weiss Ratings upgraded shares of STERIS from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 9th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $283.50.
Check Out Our Latest Report on STERIS
About STERIS
STERIS plc (NYSE: STE) provides infection prevention and procedural products and services for healthcare, pharmaceutical, research, and other industries. Its offerings include sterilizers, washers and other equipment used to clean and sterilize medical devices and surgical instruments, as well as products for operating rooms and endoscopy procedures. The company also provides equipment installation, maintenance, repair, and training, along with contract sterilization and laboratory testing services.
Further Reading
- Five stocks we like better than STERIS
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
